Keros Therapeutics, Inc.
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. T…
Biotechnology
US, Lexington [HQ]
Financials
Analysts
Wall Street · Earnings · Institutional SentimentA comprehensive analysis section that covers unveiling insights about Keros Therapeutics, Inc.'s gradings, price targets and earnings estimates. None
| FY | EPS | Revenue [mil.] | Profit [mil.] | EBITDA [mil.] | EBIT [mil.] | Expenses · SGA [mil.] | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E | E | E | E | E | E | |||||||
| 2021 | -2.9300 | -3.143 | 0 | 0.10 | -45 | -92 | -44 | 0.02 | -44 | 0.02 | 12 | 4 |
| 2022 | -2.5200 | -4.163 | 20 | 1 | -58 | -122 | -56 | 0.20 | -57 | 0.20 | 21 | 46 |
| 2023 | -4.1500 | -5.240 | 0 | 0.00 | -104 | -152 | -103 | 0.00 | -109 | 0.00 | 27 | 0.10 |
| 2024 | - | -5.189 | - | 0.55 | - | -83 | - | 0.11 | - | 0.11 | - | 25 |
| 2025 | - | -5.025 | - | 3 | - | -146 | - | 0.77 | - | 0.77 | - | 179 |
| 2026 | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F5X/td> | - | 2.F51/td> | - | 2.F51 | - | 2.F51 |
| 2027 | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F6X/td> | - | 1.F61/td> | - | 1.F61 | - | 1.F61 |
| 2028 | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F7X/td> | - | 0.F71/td> | - | 0.F71 | - | 0.F71 |